Key clinical point: About two-thirds of patients with chronic migraine (CM) showed response to galcanezumab, and everyday headache, presence of depression, and absence of accompanying symptoms were independent predictors of a poor response to galcanezumab treatment.
Major finding: After 3 months, 64.3% of patients receiving galcanezumab achieved ≥50% reduction in monthly migraine days, with everyday headache (odds ratio [OR] 0.351; P = .017), presence of depression (OR 0.439; P = .024), and absence of accompanying symptoms (OR 0.314; P = .020) being significant predictors of response to galcanezumab.
Study details: The data come from a real -world, prospective observational study including 238 patients aged ≥18 years with CM who received preventive treatment with galcanezumab injections for 3 months.
Disclosures: This study did not report the source of funding. BK Kim declared receiving honoraria and personal fees, serving on advisory boards, and being a principal investigator of trials sponsored by various sources.
Source: Lee HC et al. Predictors of response to galcanezumab in patients with chronic migraine: A real-world prospective observational study. Neurol Sci. 2023 (Feb 24). Doi: 10.1007/s10072-023-06683-2.